Literature DB >> 1915385

Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis.

S De Wit1, D Urbain, F Rahir, D Weerts, N Clumeck.   

Abstract

To assess the efficacy and tolerance of fluconazole in the treatment of oesophageal candidiasis, 47 AIDS patients with this infection were enrolled in an open prospective study using fluconazole 100 mg given orally once daily. Clinical cure was obtained in all of 41 evaluable patients, with confirmation of cure in all of 31 patients who underwent post-treatment oesophagoscopy. Forty patients were followed up for at least 30 days; none suffered a relapse of oesophagitis but seven had a recurrence of stomatitis which was effectively treated with fluconazole. Fluconazole was well tolerated. Nausea was noted in three patients one of whom interrupted therapy. Transient mild elevation of ALT/AST was noted in five of 41 patients (12%). Fluconazole appears to be a safe and effective agent for oral therapy of oesophageal candidiasis associated with AIDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915385     DOI: 10.1007/bf01963937

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS).

Authors:  G Lake-Bakaar; E Quadros; S Beidas; M Elsakr; W Tom; D E Wilson; H P Dincsoy; P Cohen; E W Straus
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

Review 2.  Current concepts. Treatment of infections associated with human immunodeficiency virus.

Authors:  A E Glatt; K Chirgwin; S H Landesman
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

Review 3.  Treatable aspects of infection due to human immunodeficiency virus.

Authors:  L S Young
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

4.  Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome.

Authors:  G M Connolly; D Hawkins; J N Harcourt-Webster; P A Parsons; O A Husain; B G Gazzard
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

5.  The acquired immunodeficiency syndrome in Haiti.

Authors:  J W Pape; B Liautaud; F Thomas; J R Mathurin; M M St Amand; M Boncy; V Pean; M Pamphile; A C Laroche; J Dehovitz
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

6.  Acquired immunodeficiency syndrome in a heterosexual population in Zaire.

Authors:  P Piot; T C Quinn; H Taelman; F M Feinsod; K B Minlangu; O Wobin; N Mbendi; P Mazebo; K Ndangi; W Stevens
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

7.  Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome.

Authors:  A Tavitian; J P Raufman; L E Rosenthal; J Weber; C A Webber; H P Dincsoy
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

8.  Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS).

Authors:  G Lake-Bakaar; W Tom; D Lake-Bakaar; N Gupta; S Beidas; M Elsakr; E Straus
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

9.  Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends.

Authors:  R M Selik; E T Starcher; J W Curran
Journal:  AIDS       Date:  1987-09       Impact factor: 4.177

Review 10.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more
  9 in total

Review 1.  Fluconazole in the treatment of fungal infections associated with AIDS.

Authors:  S De Wit; N Clumeck
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

2.  Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study.

Authors:  M G Agresti; F de Bernardis; F Mondello; R Bellocco; G P Carosi; R M Caputo; F Milazzo; F Chiodo; V Giannini; L Minoli
Journal:  Eur J Epidemiol       Date:  1994-02       Impact factor: 8.082

3.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

Review 4.  Invasive oesophageal candidiasis: current and developing treatment options.

Authors:  Jose A Vazquez
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype.

Authors:  L Millon; A Manteaux; G Reboux; C Drobacheff; M Monod; T Barale; Y Michel-Briand
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

6.  Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection.

Authors:  M C Nahata; M T Brady
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

Authors:  Jose A Vazquez
Journal:  HIV AIDS (Auckl)       Date:  2010-04-28

8.  Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses.

Authors:  Nancy A Chow; José F Muñoz; Anastasia P Litvintseva; Christina A Cuomo; Lalitha Gade; Elizabeth L Berkow; Xiao Li; Rory M Welsh; Kaitlin Forsberg; Shawn R Lockhart; Rodney Adam; Alexandre Alanio; Ana Alastruey-Izquierdo; Sahar Althawadi; Ana Belén Araúz; Ronen Ben-Ami; Amrita Bharat; Belinda Calvo; Marie Desnos-Ollivier; Patricia Escandón; Dianne Gardam; Revathi Gunturu; Christopher H Heath; Oliver Kurzai; Ronny Martin
Journal:  mBio       Date:  2020-04-28       Impact factor: 7.867

9.  Infectious Esophagitis.

Authors:  Brian P. Mulhall; Roy K. H. Wong
Journal:  Curr Treat Options Gastroenterol       Date:  2003-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.